Milena Mary de Souza Andrade

Mrs. Milena Mary de Souza Andrade

USP, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
MAMilena Mary de Souza Andrade
Milena Mary de Souza Andrade
VLVinicius Nunes Cordeiro Leal
Vinicius Nunes Cordeiro Leal
IFIara Grigoletto Fernandes
Iara Grigoletto Fernandes
SGSarah Gozzi-Silva
Sarah Gozzi-Silva
DBDanielle R. Beserra
Danielle R. Beserra
MSMaria Notomi Sato
Maria Notomi Sato
The formation of microthrombi in lung autopsies indicates the involvement of NETs in the immunopathogenesis of severe COVID-19. Therefore, supplements inhibiting NET formation, in association with drugs with fewer adverse effects, should be a relevant strategy to attenuate the disease. Resveratrol (RESV) is a natural polyphenol with an important antiviral and antioxidant role. To modulate neutrophils from patients infected with SARS-CoV-2, we evaluated the in vitro effect of RESV on NET formation. Herein, we investigated 190 patients hospitalized with moderate, severe, and critical symptoms at Hospital das Clínicas, Brazil. We observed that neutrophilia in patients with severe COVID-19 infection is composed of neutrophils with activated profile able to release NET spontaneously. Notably, RESV decreased the neutrophil-activated status and the release of free DNA, inhibiting NET formation even under the specific PMA stimulus. At present, there is no evidence of the role of RESV in neutrophils from patients with COVID-19 infection. These findings suggest that adjunctive therapies with RESV may help decrease the inflammation of viral or bacterial infection, improving patient outcomes.

1 August 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
DBDanielle Rosa Beserra
Danielle Rosa Beserra
RARicardo Wesley Alberca
Ricardo Wesley Alberca
ABAnna Claudia Calvielli Castelo Branco
Anna Claudia Calvielli Castelo Branco
LOLuana de Mendonça Oliveira
Luana de Mendonça Oliveira
MAMilena Mary de Souza Andrade
Milena Mary de Souza Andrade
MSMaria Notomi Sato
Maria Notomi Sato
COVID-19 has several mechanisms that can lead to lymphocyte depletion/exhaustion. The checkpoint inhibitor molecule programmed death protein 1 (PD-1) and its programmed death-ligand 1 (PDL-1) play an important role in inhibiting cellular activity as well as the depletion of these cells. In this study, we evaluated PD-1 expression in TCD4+, TCD8+, and CD19+ lymphocytes from SARS-CoV-2-infected patients. A decreased frequency of total lymphocytes and an increased PD-1 expression in TCD4+ and CD19+ lymphocytes were verified in severe/critical COVID-19 patients. In addition, we found a decreased frequency of total monocytes with an increased PD-1 expression on CD14+ monocytes in severe/critical patients in association with the time of infection. Moreover, we observed an increase in sPD-L1 circulant levels associated with the severity of the disease. Overall, these data indicate an important role of the PD-1/PDL-1 axis in COVID-19 and may provide a severity-associated biomarker and therapeutic target during SARS-CoV-2 infection.

2 December 2020 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
RARicardo Wesley Alberca
Ricardo Wesley Alberca
TYTatiana Mina Yendo
Tatiana Mina Yendo
YRYasmim LEUZZI RAMOS
Yasmim LEUZZI RAMOS
IFIara Grigoletto Fernandes
Iara Grigoletto Fernandes
LOLuana de Mendonça Oliveira
Luana de Mendonça Oliveira
MSMaria Notomi Sato
Maria Notomi Sato
American trypanosomiasis, also named Chagas disease (CD), is an anthropozoonosis caused by the protozoan parasite Trypanosoma cruzi. The disease affects millions of people worldwide, leading yearly to approximately 50,000 deaths. COVID-19, generated by SARS-CoV-2, can lead to lymphopenia and death. We hereby describe the first report of two patients with CD and COVID-19 coinfection, from hospitalization until patients’ death.

25 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
SGSarah Gozzi-Silva
Sarah Gozzi-Silva
LOLuana de Mendonça Oliveira
Luana de Mendonça Oliveira
RARicardo Wesley Alberca
Ricardo Wesley Alberca
NPNátalli Zanete Pereira
Nátalli Zanete Pereira
FYFabio Seiti Yamada Yoshikawa
Fabio Seiti Yamada Yoshikawa
MSMaria Notomi Sato
Maria Notomi Sato
COVID-19, the infectious disease caused by SARS-CoV-2, has spread on a pandemic scale. The viral infection can evolve asymptomatically or can generate severe symptoms, influenced by the presence of comorbidities. Lymphopenia based on the severity of symptoms in patients affected with COVID-19 is frequent. However, the profiles of CD4+ and CD8+ T cells regarding cytotoxicity and antiviral factor expression have not yet been completely elucidated in acute SARS-CoV-2 infections. The purpose of this study was to evaluate the phenotypic and functional profile of T lymphocytes in patients with moderate and severe/critical COVID-19. During the pandemic period, we analyzed a cohort of 62 confirmed patients with SARS-CoV-2 (22 moderate cases and 40 severe/critical cases). Notwithstanding lymphopenia, we observed an increase in the expression of CD28, a co-stimulator molecule, and activation markers (CD38 and HLA-DR) in T lymphocytes as well as an increase in the frequency of CD4+ T cells, CD8+ T cells, and NK cells that express the immunological checkpoint protein PD-1 in patients with a severe/critical condition compared to healthy controls. Regarding the cytotoxic profile of peripheral blood mononuclear cells, an increase in the response of CD4+ T cells was already observed at the baseline level and scarcely changed upon PMA and Ionomycin stimulation. Meanwhile, CD8+ T lymphocytes decreased the cytotoxic response, evidencing a profile of exhaustion in patients with severe COVID-19. As observed by t-SNE, there were CD4+ T-cytotoxic and CD8+ T with low granzyme production, evidencing their dysfunction in severe/critical conditions. In addition, purified CD8+ T lymphocytes from patients with severe COVID-19 showed increased constitutive expression of differentially expressed genes associated with the caspase pathway, inflammasome, and antiviral factors, and, curiously, had reduced expression of TNF-α. The cytotoxic profile of CD4+ T cells may compensate for the dysfunction/exhaustion of TCD8+ in acute SARS-CoV-2 infection. These findings may provide an understanding of the interplay of cytotoxicity between CD4+ T cells and CD8+ T cells in the severity of acute COVID-19 infection.

Verified
Journal Article
Open access
PDF file
IFIara Grigoletto Fernandes
Iara Grigoletto Fernandes
LOLuana de Mendonça Oliveira
Luana de Mendonça Oliveira
MAMilena Mary de Souza Andrade
Milena Mary de Souza Andrade
RARicardo Wesley Alberca
Ricardo Wesley Alberca
JLJúlia Cataldo Lima
Júlia Cataldo Lima
MSMaria Notomi Sato
Maria Notomi Sato
Immunosenescence, a process with a dysfunctional immune response that may favor infection is associated with an increase in inflammatory responses mediated by proinflammatory cytokines, characteristic of inflammaging. Aging and immunosenescence have a relationship relating to oxidative stress and inflammaging. Therefore, natural antioxidant compounds could be candidates for the control of the oxidative process. Our purpose was to evaluate the effect of resveratrol (Resv) on the antioxidant, antiviral, and anti-inflammatory responses induced by toll-like receptors (TLRs) 3, 4, and 7/8 agonists stimulation on peripheral blood mononuclear cells (PBMCs) of elderly and healthy female individuals (63–82 years old) and young and healthy female individuals (21–31 years old). Our data show that Resv may upregulate antioxidant factor expression, such as catalase (CAT) and SIRT1, in response to TLR4 and TLR7/8 agonists, similarly in both young and aged groups. Moreover, the Resv anti-inflammatory effect was detected by inhibiting IL-1β, TNF-α, and IL-10 secretion levels, as well as by the chemokines CCL2 and CCL5, induced by TLR4 and TLR7/8 stimulation. Curiously, Resv decreased antiviral genes, such as MxA, STING, and IRF7 expression, possibly by reducing the inflammatory effects of interferon-induced genes. Taken together, our results demonstrate the ability of Resv to stimulate antioxidant factors, leading to a downmodulation of the inflammatory response induced by innate immune stimulation. These findings point out Resv as a strategy to control the upregulation of inflammatory response, even in elderly individuals.

24 September 2021 in Life
Verified
Journal Article
Open access
PDF file
RARicardo Wesley Alberca
Ricardo Wesley Alberca
RSRosa Liliana Solis-Castro
Rosa Liliana Solis-Castro
María Edith Solis-CastroMaría Edith Solis-Castro
María Edith Solis-Castro
FCFernanda Cardoso
Fernanda Cardoso
ADAlberto Jose da Silva Duarte
Alberto Jose da Silva Duarte
MSMaria Notomi Sato
Maria Notomi Sato
Coronavirus disease 2019 (COVID-19) caused millions of deaths worldwide. COVID-19’s clinical manifestations range from no symptoms to a severe acute respiratory syndrome, which can result in multiple organ failure, sepsis, and death. Severe COVID-19 patients develop pulmonary and extrapulmonary infections, with a hypercoagulable state. Several inflammatory or coagulatory biomarkers are currently used with predictive values for COVID-19 severity and prognosis. In this manuscript, we investigate if a combination of coagulatory and inflammatory biomarkers could provide a better biomarker with predictive value for COVID-19 patients, being able to distinguish between patients that would develop a moderate or severe COVID-19 and predict the disease outcome. We investigated 306 patients with COVID-19, confirmed by severe acute respiratory syndrome coronavirus 2 RNA detected in the nasopharyngeal swab, and retrospectively analyzed the laboratory data from the first day of hospitalization. In our cohort, biomarkers such as neutrophil count and neutrophil-to-lymphocyte ratio from the day of hospitalization could predict if the patient would need to be transferred to the intensive care unit but failed to identify the patients´ outcomes. The ratio between platelets and inflammatory markers such as creatinine, C-reactive protein, and urea levels is associated with patient outcomes. Finally, the platelet/neutrophil-to-lymphocyte ratio on the first day of hospitalization can be used with predictive value as a novel severity and lethality biomarker in COVID-19. These new biomarkers with predictive value could be used routinely to stratify the risk in COVID-19 patients since the first day of hospitalization.